AP3340A - Novel compounds as histamine H3 receptor ligands - Google Patents

Novel compounds as histamine H3 receptor ligands

Info

Publication number
AP3340A
AP3340A AP2013007088A AP2013007088A AP3340A AP 3340 A AP3340 A AP 3340A AP 2013007088 A AP2013007088 A AP 2013007088A AP 2013007088 A AP2013007088 A AP 2013007088A AP 3340 A AP3340 A AP 3340A
Authority
AP
ARIPO
Prior art keywords
histamine
novel compounds
receptor ligands
ligands
receptor
Prior art date
Application number
AP2013007088A
Other languages
English (en)
Other versions
AP2013007088A0 (en
Inventor
Narasimhareddy Gangadasari
Sangram Keshari Saraf
Amol Dinakar Deshpande
Original Assignee
Suven Life Science Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suven Life Science Ltd filed Critical Suven Life Science Ltd
Publication of AP2013007088A0 publication Critical patent/AP2013007088A0/xx
Application granted granted Critical
Publication of AP3340A publication Critical patent/AP3340A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/44Oxygen atoms attached in position 4
    • C07D211/46Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
AP2013007088A 2011-02-23 2011-06-07 Novel compounds as histamine H3 receptor ligands AP3340A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN520CH2011 2011-02-23
PCT/IN2011/000380 WO2012114348A1 (en) 2011-02-23 2011-06-07 Novel compounds as histamine h3 receptor ligands

Publications (2)

Publication Number Publication Date
AP2013007088A0 AP2013007088A0 (en) 2013-08-31
AP3340A true AP3340A (en) 2015-07-31

Family

ID=54290090

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2013007088A AP3340A (en) 2011-02-23 2011-06-07 Novel compounds as histamine H3 receptor ligands

Country Status (27)

Country Link
US (1) US9079888B2 (me)
EP (1) EP2694492B1 (me)
JP (1) JP5805792B2 (me)
KR (1) KR101554407B1 (me)
CN (1) CN103443093B (me)
AP (1) AP3340A (me)
AU (1) AU2011360550B2 (me)
BR (1) BR112013021496B1 (me)
CA (1) CA2827567C (me)
CY (1) CY1116721T1 (me)
DK (1) DK2694492T3 (me)
EA (1) EA023260B1 (me)
ES (1) ES2548284T3 (me)
HR (1) HRP20151003T1 (me)
HU (1) HUE025163T2 (me)
IL (1) IL228019A (me)
ME (1) ME02212B (me)
MX (1) MX339858B (me)
NZ (1) NZ614567A (me)
PL (1) PL2694492T3 (me)
PT (1) PT2694492E (me)
RS (1) RS54248B1 (me)
SG (1) SG192858A1 (me)
SI (1) SI2694492T1 (me)
SM (1) SMT201500238B (me)
WO (1) WO2012114348A1 (me)
ZA (1) ZA201306328B (me)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP1300139A2 (en) * 2013-03-06 2014-09-29 Richter Gedeon Nyrt Phenoxypiperidine h3 antagonists
EA032823B1 (ru) * 2014-08-16 2019-07-31 Сувен Лайф Сайенсиз Лимитед Способ получения n-[4-(1-циклобутилпиперидин-4-илокси)фенил]-2-(морфолин-4-ил)ацетамиддигидрохлорида в большом масштабе
PL3500306T3 (pl) * 2016-08-18 2021-02-08 Suven Life Sciences Limited Potrójne połączenie odwrotnych agonistów receptora histaminowego-3, inhibitorów acetylocholinoesterazy i antagonisty receptora nmda
EA032957B1 (ru) * 2016-08-18 2019-08-30 Сувен Лайф Сайенсиз Лимитед Комбинация обратных агонистов гистамин-3 рецептора с ингибиторами ацетилхолинэстеразы
MA52850B1 (fr) * 2018-05-31 2025-03-28 Suven Life Sciences Limited Méthode de traitement avec un agoniste inverse du récepteur de l'histamine-3
WO2022113008A1 (en) 2020-11-27 2022-06-02 Richter Gedeon Nyrt. Histamine h3 receptor antagonists/inverse agonists for the treatment of autism spectrum disorder
WO2023166351A1 (zh) * 2022-03-02 2023-09-07 杭州百诚医药科技股份有限公司 组胺h3受体抑制剂及其医药用途
WO2023166349A2 (zh) * 2022-03-02 2023-09-07 杭州百诚医药科技股份有限公司 苯基脲类衍生物及其医药用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100048580A1 (en) * 2004-04-01 2010-02-25 Lisa Selsam Beavers Histamine h3 receptor agents, preparation and therapeutic uses
WO2010045306A2 (en) * 2008-10-16 2010-04-22 Schering Corporation Azine derivatives and methods of use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9725541D0 (en) * 1997-12-02 1998-02-04 Pharmacia & Upjohn Spa Amino-benzothiazole derivatives
EP1311482B1 (en) * 2000-08-08 2007-02-21 Ortho-McNeil Pharmaceutical, Inc. Non-imidazole aryloxypiperidines as h3 receptor ligands
JP2004532834A (ja) * 2001-03-23 2004-10-28 イーライ・リリー・アンド・カンパニー ヒスタミンh3受容体アンタゴニストである非イミダゾール系アリールアルキルアミン化合物、その製造および治療的使用
EP2186516B1 (en) * 2002-12-20 2013-01-16 Glaxo Group Limited Novel benzazepine derivative
JP4777974B2 (ja) * 2004-04-01 2011-09-21 イーライ リリー アンド カンパニー ヒスタミンh3受容体作用物質、製剤および治療的使用
BRPI0514553A (pt) 2004-08-23 2008-06-17 Lilly Co Eli composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos para inibir o receptor de histamina h3 em um mamìfero, para o tratamento de um distúrbio do sistema nervoso, para o tratamento de obesidade e para o tratamento de um distúrbio ou doença, e, uso de um composto ou um sal do mesmo
JP5379796B2 (ja) 2007-09-06 2013-12-25 グラクソ グループ リミテッド ヒスタミンh3受容体に対しアフィニティーを有するピペラジン誘導体
AU2008312641A1 (en) * 2007-10-17 2009-04-23 Sanofi-Aventis Substituted N-phenyl-bipyrrolidine ureas and therapeutic use thereof
US7799816B2 (en) 2008-02-04 2010-09-21 Roche Palo Alto Llc Imidazolinylmethyl aryl sulfonamide
EP2268638A1 (en) 2008-03-31 2011-01-05 Evotec AG Tetrahydronaphthyridines and aza derivatives thereof as histamine h3 receptor antagonists
US8691804B2 (en) 2008-05-08 2014-04-08 Evotec Ag Azetidines and cyclobutanes as histamine H3 receptor antagonists

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100048580A1 (en) * 2004-04-01 2010-02-25 Lisa Selsam Beavers Histamine h3 receptor agents, preparation and therapeutic uses
WO2010045306A2 (en) * 2008-10-16 2010-04-22 Schering Corporation Azine derivatives and methods of use thereof

Also Published As

Publication number Publication date
AU2011360550A1 (en) 2013-09-12
US9079888B2 (en) 2015-07-14
AU2011360550B2 (en) 2015-04-09
AP2013007088A0 (en) 2013-08-31
KR101554407B1 (ko) 2015-09-18
CN103443093B (zh) 2015-02-25
CA2827567C (en) 2015-10-27
ME02212B (me) 2016-02-20
SI2694492T1 (sl) 2015-11-30
BR112013021496A2 (pt) 2019-08-06
HUE025163T2 (en) 2016-02-29
HK1187613A1 (en) 2014-04-11
PT2694492E (pt) 2015-10-19
DK2694492T3 (en) 2015-11-09
US20140135304A1 (en) 2014-05-15
CY1116721T1 (el) 2017-03-15
SMT201500238B (it) 2015-10-30
JP5805792B2 (ja) 2015-11-10
RS54248B1 (sr) 2016-02-29
EA023260B1 (ru) 2016-05-31
HRP20151003T1 (hr) 2015-10-23
WO2012114348A1 (en) 2012-08-30
MX339858B (es) 2016-06-15
CA2827567A1 (en) 2012-08-30
NZ614567A (en) 2014-07-25
KR20130133270A (ko) 2013-12-06
BR112013021496B1 (pt) 2021-10-13
SG192858A1 (en) 2013-09-30
ZA201306328B (en) 2014-04-30
IL228019A (en) 2015-11-30
EA201391211A1 (ru) 2014-06-30
ES2548284T3 (es) 2015-10-15
MX2013009683A (es) 2013-10-28
PL2694492T3 (pl) 2015-12-31
EP2694492A1 (en) 2014-02-12
JP2014508761A (ja) 2014-04-10
CN103443093A (zh) 2013-12-11
IL228019A0 (en) 2013-09-30
EP2694492B1 (en) 2015-07-29

Similar Documents

Publication Publication Date Title
GB201106799D0 (en) Novel compounds
GB201107325D0 (en) Novel compounds
GB201112607D0 (en) Novel compounds
ZA201306328B (en) Novel compounds as histamine h3 receptor ligands
EP2717694A4 (en) NEW COMPOUNDS
GB201111704D0 (en) Novel compounds
IL231305A0 (en) Heteroaryl compounds as ligands for the 4 th –5 receptor
IL236437A0 (en) Acrylamide compounds as ligands for the histamine h3 receptor
ZA201301143B (en) Heterocyclyl compounds as histamine h3 receptor ligands
ZA201409244B (en) Acrylamide compounds as histamine h3 receptor ligands
GB201111409D0 (en) Novel compounds
GB201111308D0 (en) Novel compounds
GB201121358D0 (en) Novel compounds
GB201121360D0 (en) Novel compounds
GB201111476D0 (en) Novel compounds
GB201101085D0 (en) Novel compounds
GB201101640D0 (en) Novel compounds
GB201103073D0 (en) Novel compounds
GB201104138D0 (en) Novel compounds
GB201121357D0 (en) Novel compounds
GB201106801D0 (en) Novel compounds
GB201109508D0 (en) Novel compounds
GB201109514D0 (en) Novel compounds
GB201111229D0 (en) Novel compounds
GB201111410D0 (en) Novel compounds